Evidence map›Paper›PMID 31340628›Full record

ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2019

[Comparative study of molecular response of first-line and second-line nilotinib in patients with chronic-phase chronic myelogenous leukemia].

H Xu, P Wang, R J Ma, J M Guo, P C Lei, Y Z Zang, T B Wang, Z W Liu, J Yang, Y Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

H XuJinzhou Medical University, Jinzhou 121001, China; Hematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
P WangHematology of Department, Xinyang Central Hospital, Xinyang 464000, China.
R J MaHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
J M GuoHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
P C LeiHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
Y Z ZangHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
T B WangHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
Z W LiuHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
J YangHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
Y ZhangHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China.
Z M ZhuHematology of Department, Henan Province People's Hospital, Zhengzhou 450003, China; Institute of Hematology, Henan Province People's Hospital, Zhengzhou 450003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, Chronic-PhaseAntineoplastic AgentsDasatinibHumansProtein Kinase InhibitorsPyrimidinesAntineoplastic AgentsDasatinibnilotinibProtein Kinase InhibitorsPyrimidines

Identifiers

PMID31340628
PMCPMC7342397

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.